
CRISPR Therapeutics AG CRSP
$ 45.05
-10.06%
CRISPR Therapeutics AG EV/EBITDA Ratio | CRSP
Annual EV/EBITDA Ratio CRISPR Therapeutics AG
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.79 | -7.49 | -31.8 | -5.85 | 13.2 | -26.3 | 37.1 | -7.01 | -23.2 | 1.46 | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 37.1 | -31.8 | -5.68 |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MeiraGTx Holdings plc
MGTX
|
-8.94 | $ 9.62 | 1.37 % | $ 774 M | ||
|
Processa Pharmaceuticals
PCSA
|
-0.0598 | $ 1.86 | -4.62 % | $ 2.44 M | ||
|
Eton Pharmaceuticals
ETON
|
187 | $ 67.5 | 4.9 % | $ 1.82 B | ||
|
IDEAYA Biosciences
IDYA
|
-17.2 | $ 31.72 | -0.97 % | $ 2.81 B | ||
|
Protalix BioTherapeutics
PLX
|
-47.8 | $ 2.86 | 11.28 % | $ 225 M | ||
|
Lantern Pharma
LTRN
|
-0.757 | $ 0.47 | -22.86 % | $ 5.12 M | ||
|
Foghorn Therapeutics
FHTX
|
-7 | $ 1.89 | -7.35 % | $ 119 M | ||
|
Ocugen
OCGN
|
-10.8 | $ 0.95 | -2.45 % | $ 297 M | ||
|
Oncolytics Biotech
ONCY
|
-1.33 | $ 0.38 | -5.64 % | $ 36.4 M | ||
|
Minerva Neurosciences
NERV
|
-14.1 | $ 2.47 | -6.08 % | $ 20.9 M | ||
|
Kamada Ltd.
KMDA
|
15.8 | $ 8.09 | 4.93 % | $ 466 M | ||
|
Neurocrine Biosciences
NBIX
|
1.03 | $ 169.08 | 0.13 % | $ 16.8 B | ||
|
Nanobiotix S.A.
NBTX
|
-134 K | $ 32.8 | 2.4 % | $ 1.57 T | ||
|
Mereo BioPharma Group plc
MREO
|
-16.6 | $ 0.3 | 1.66 % | $ 239 M | ||
|
Maravai LifeSciences Holdings
MRVI
|
-2.55 | $ 7.86 | -2.31 % | $ 1.13 B | ||
|
Lexicon Pharmaceuticals
LXRX
|
-13.1 | $ 1.84 | 0.82 % | $ 668 M | ||
|
Moleculin Biotech
MBRX
|
-0.0282 | $ 8.01 | -7.51 % | $ 9.49 M | ||
|
Nurix Therapeutics
NRIX
|
-5.31 | $ 15.89 | -1.58 % | $ 1.38 B | ||
|
Nkarta
NKTX
|
-1.86 | $ 1.36 | -14.78 % | $ 101 M | ||
|
MacroGenics
MGNX
|
-4.46 | $ 2.42 | 3.42 % | $ 153 M | ||
|
Protagonist Therapeutics
PTGX
|
-34.8 | $ 136.18 | 0.2 % | $ 8.66 B | ||
|
Nuvation Bio
NUVB
|
-10 | $ 4.22 | -3.1 % | $ 1.44 B | ||
|
Novo Nordisk A/S
NVO
|
3.62 | $ 40.6 | -1.88 % | $ 180 B | ||
|
Marker Therapeutics
MRKR
|
-0.521 | $ 0.95 | -3.87 % | $ 14.5 M | ||
|
NextCure
NXTC
|
-0.872 | $ 5.97 | -4.78 % | $ 17 M | ||
|
Rocket Pharmaceuticals
RCKT
|
-1.27 | $ 2.46 | -2.96 % | $ 273 M | ||
|
PMV Pharmaceuticals
PMVP
|
-0.691 | $ 1.22 | -2.8 % | $ 64.1 M | ||
|
Olema Pharmaceuticals
OLMA
|
-8.14 | $ 7.29 | -1.02 % | $ 634 M | ||
|
Kymera Therapeutics
KYMR
|
-22.7 | $ 136.45 | -1.74 % | $ 11.5 B | ||
|
Oragenics
OGEN
|
0.0948 | $ 0.35 | -1.47 % | $ 755 K | ||
|
Ovid Therapeutics
OVID
|
-7.27 | $ 2.8 | -1.75 % | $ 365 M | ||
|
Passage Bio
PASG
|
-1.89 | $ 3.81 | 11.08 % | $ 12.2 M | ||
|
Vaxcyte
PCVX
|
-9.39 | $ 66.44 | -1.61 % | $ 9.04 B | ||
|
Relay Therapeutics
RLAY
|
-1.72 | $ 19.81 | -2.87 % | $ 3.4 B | ||
|
Precigen
PGEN
|
-10 | $ 4.51 | -4.76 % | $ 1.41 B | ||
|
Avidity Biosciences
RNA
|
-13.4 | $ 8.23 | -1.79 % | $ 1.13 B | ||
|
Phio Pharmaceuticals Corp.
PHIO
|
1.37 | $ 0.82 | -2.07 % | $ 4.91 M | ||
|
Praxis Precision Medicines
PRAX
|
-21.5 | $ 337.69 | 1.42 % | $ 7.6 B | ||
|
Prelude Therapeutics Incorporated
PRLD
|
-3.06 | $ 3.78 | 0.53 % | $ 291 M | ||
|
ProQR Therapeutics N.V.
PRQR
|
-3.07 | $ 1.31 | -5.07 % | $ 138 M | ||
|
Ocular Therapeutix
OCUL
|
-4.23 | $ 6.62 | -3.36 % | $ 1.24 B | ||
|
PolyPid Ltd.
PYPD
|
-1.95 | $ 6.3 | 0.96 % | $ 103 M | ||
|
Outlook Therapeutics
OTLK
|
-1.56 | $ 0.46 | -0.84 % | $ 16 M | ||
|
uniQure N.V.
QURE
|
-6.87 | $ 22.7 | -0.39 % | $ 1.31 B | ||
|
Ultragenyx Pharmaceutical
RARE
|
-6.39 | $ 16.13 | -1.71 % | $ 1.59 B | ||
|
Rafael Holdings
RFL
|
-1.45 | $ 1.11 | 2.45 % | $ 57 M | ||
|
REGENXBIO
RGNX
|
-5.22 | $ 7.66 | -5.08 % | $ 395 M | ||
|
Rigel Pharmaceuticals
RIGL
|
5.31 | $ 43.83 | 4.22 % | $ 788 M | ||
|
SELLAS Life Sciences Group
SLS
|
-17.8 | $ 8.38 | -2.39 % | $ 914 M | ||
|
Celsion Corporation
CLSN
|
0.248 | - | -6.63 % | $ 13.9 M |